{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:22:10Z","timestamp":1777555330445,"version":"3.51.4"},"reference-count":68,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite a strong rationale for intraperitoneal (IP) chemotherapy, the actual use of the procedure is limited by the poor penetration depth of the drug into the tissue. Drug penetration into solid tumours is a complex mass transport process that involves multiple parameters not only related to the used cytotoxic agent but also to the tumour tissue properties and even the therapeutic setup. Mathematical modelling can provide unique insights into the different transport barriers that occur during IP chemotherapy as well as offer the possibility to test different protocols or drugs without the need for\n                    <jats:italic>in vivo<\/jats:italic>\n                    experiments. In this work, a distinction is made between three different types of model: the lumped parameter model, the distributed model and the cell-based model. For each model, we discuss which steps of the transport process are included and where assumptions are made. Finally, we focus on the advantages and main limitations of each category and discuss some future perspectives for the modelling of IP chemotherapy.\n                  <\/jats:p>","DOI":"10.1515\/pp-2017-0004","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T06:01:38Z","timestamp":1492581698000},"page":"73-83","source":"Crossref","is-referenced-by-count":24,"title":["Modelling drug transport during intraperitoneal chemotherapy"],"prefix":"10.1515","volume":"2","author":[{"given":"Margo","family":"Steuperaert","sequence":"first","affiliation":[{"name":"Biofluid, Tissue and Solid Mechanics for Medical Applications (bioMMeda) , Department of Electronics and Information Systems, iMinds Medical IT Department, Ghent University , Ghent , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Debbaut","sequence":"additional","affiliation":[{"name":"Biofluid, Tissue and Solid Mechanics for Medical Applications (bioMMeda) , Department of Electronics and Information Systems, iMinds Medical IT Department, Ghent University , Ghent , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Segers","sequence":"additional","affiliation":[{"name":"Biofluid, Tissue and Solid Mechanics for Medical Applications (bioMMeda) , Department of Electronics and Information Systems, iMinds Medical IT Department, Ghent University , Ghent , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Ceelen","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer Research Institute Ghent (CRIG) , Ghent University , Ghent , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,4,14]]},"reference":[{"key":"2025120909204645922_j_pp-2017-0004_ref_001_w2aab3b7c16b1b6b1ab2b1b1Aa","unstructured":"Dedrick R, Myers C, Bungay P, DeVita V. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1\u201311."},{"key":"2025120909204645922_j_pp-2017-0004_ref_002_w2aab3b7c16b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Hasovits C, Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin Pharmacokinet 2012;51:203\u201324.","DOI":"10.2165\/11598890-000000000-00000"},{"key":"2025120909204645922_j_pp-2017-0004_ref_003_w2aab3b7c16b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin\u2014A Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol 2005;99:591\u20136.","DOI":"10.1016\/j.ygyno.2005.06.055"},{"key":"2025120909204645922_j_pp-2017-0004_ref_004_w2aab3b7c16b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Ceelen W, Flessner M. Intraperitoneal therapy for peritoneal tumors: Biophysics and clinical evidence. Nat Rev Clin Oncol 2010;7:108\u201315.","DOI":"10.1038\/nrclinonc.2009.217"},{"key":"2025120909204645922_j_pp-2017-0004_ref_005_w2aab3b7c16b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Nederman T, Carlsson J. Penetration and binding of vinblastine and 5\u2011fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 1984;13:131\u20135.","DOI":"10.1007\/BF00257130"},{"key":"2025120909204645922_j_pp-2017-0004_ref_006_w2aab3b7c16b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Van De Vaart P, Van Der Vange N, Zoetmulder F, Van Goethem A, Van Tellingen O, Ten Bokkel W, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin \u2013DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34:148\u201354.","DOI":"10.1016\/S0959-8049(97)00370-5"},{"key":"2025120909204645922_j_pp-2017-0004_ref_007_w2aab3b7c16b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Minchinton A, Tannock I. Drug penetration in solid tumors. Nat Rev Cancer 2006;6:583\u201392.","DOI":"10.1038\/nrc1893"},{"key":"2025120909204645922_j_pp-2017-0004_ref_008_w2aab3b7c16b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Los G, Mutsaers P, Lenglet W, Baldew G, McVie J. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 1990;25:389\u201394.","DOI":"10.1007\/BF00686048"},{"key":"2025120909204645922_j_pp-2017-0004_ref_009_w2aab3b7c16b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Ansaloni L, Coccolini F, Morosi L, Ballerini A, Ceresoli M, Grosso G, et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer 2015;112:306\u201312.","DOI":"10.1038\/bjc.2014.602"},{"key":"2025120909204645922_j_pp-2017-0004_ref_010_w2aab3b7c16b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Royer B, Kalbacher E, Onteniente S, Jullien V, Montange D, Piedoux S, et al. Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: A population pharmacokinetic study. Br J Cancer 2012;106:460\u20137.","DOI":"10.1038\/bjc.2011.557"},{"key":"2025120909204645922_j_pp-2017-0004_ref_011_w2aab3b7c16b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Kruger-Thiemer E, Eriksen S. Mathematical model of sustained-release preparations and its analysis. J Pharm Sci 1966;55:1249\u201353.","DOI":"10.1002\/jps.2600551117"},{"key":"2025120909204645922_j_pp-2017-0004_ref_012_w2aab3b7c16b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Robinson J, Eriksen S. Theoretical formulation of sustained-release dosage forms. J Pharm Sci 1966;55:1254\u201363.","DOI":"10.1002\/jps.2600551118"},{"key":"2025120909204645922_j_pp-2017-0004_ref_013_w2aab3b7c16b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Flessner M, Henegar J, Bigler S, Genous L. Is the peritoneum a significant transport barrier in peritoneal dialysis?. Perit Dial Int 2003;23:542\u20139.","DOI":"10.1177\/089686080302300605"},{"key":"2025120909204645922_j_pp-2017-0004_ref_014_w2aab3b7c16b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Vazquez V, Stuart O, Mohamed F, Sugarbaker P. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol 2003;52:108\u201312.","DOI":"10.1007\/s00280-003-0626-8"},{"key":"2025120909204645922_j_pp-2017-0004_ref_015_w2aab3b7c16b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Kerb R, M\u00fcrdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: First evidence for efficacy. Ann Surg Oncol 2014;21:553\u20139.","DOI":"10.1245\/s10434-013-3213-1"},{"key":"2025120909204645922_j_pp-2017-0004_ref_016_w2aab3b7c16b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Jang S, Wientjes M, Au JS. Enhancement of paclitaxel delivery to solid tumors by apoptosis\u2011inducing pretreatment: Effect of treatment schedule. J Pharmacol Exp Ther 2001;296:1035\u201342.","DOI":"10.1016\/S0022-3565(24)38848-2"},{"key":"2025120909204645922_j_pp-2017-0004_ref_017_w2aab3b7c16b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Kondo A, Maeta M, Oka A, Tsujitani S, Ikeguchi M, Kaibara N. Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. Br J Cancer 1996;73:1166\u201370.","DOI":"10.1038\/bjc.1996.225"},{"key":"2025120909204645922_j_pp-2017-0004_ref_018_w2aab3b7c16b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa M, et al. High intra\u2011abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg 2006;244:106\u201312.","DOI":"10.1097\/01.sla.0000218089.61635.5f"},{"key":"2025120909204645922_j_pp-2017-0004_ref_019_w2aab3b7c16b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Einstein A. \u00dcber die von der molekularkinetischen Theorie der W\u00e4rme geforderte Bewegung von in ruhenden Fl\u00fcssigkeiten suspendierten Teilchen. Annalen Der Physik 1905;322:549\u201360.","DOI":"10.1002\/andp.19053220806"},{"key":"2025120909204645922_j_pp-2017-0004_ref_020_w2aab3b7c16b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Chauhan V, Lanning R, Diop-Frimpong B, Mok W, Brown E, Padera T, et al. Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo. Biophys J 2009;97:330\u20136.","DOI":"10.1016\/j.bpj.2009.03.064"},{"key":"2025120909204645922_j_pp-2017-0004_ref_021_w2aab3b7c16b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Provenzano P, Eliceiri K, Campbell J, Inman D, White J, Keely P. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 2006;4:38.","DOI":"10.1186\/1741-7015-4-38"},{"key":"2025120909204645922_j_pp-2017-0004_ref_022_w2aab3b7c16b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Xu W, Mezencev R, Kim B, Wang L, McDonald J, Sulchek T. Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells. Batra SK, ed. Plos ONE. 2012;7:e46609. DOI:10.1371\/journal.pone.0046609.","DOI":"10.1371\/journal.pone.0046609"},{"key":"2025120909204645922_j_pp-2017-0004_ref_023_w2aab3b7c16b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Heldin C, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806\u201313.","DOI":"10.1038\/nrc1456"},{"key":"2025120909204645922_j_pp-2017-0004_ref_024_w2aab3b7c16b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Jain R, Cook A, Steele E. Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radiat Biol 1991;60:85\u2013100.","DOI":"10.1080\/09553009114551621"},{"key":"2025120909204645922_j_pp-2017-0004_ref_025_w2aab3b7c16b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"El-Kareh AW, Secomb TW. A mathematical model for cisplatin cellular pharmacodynamics. Neoplasia 2003;5:161\u20139.","DOI":"10.1016\/S1476-5586(03)80008-8"},{"key":"2025120909204645922_j_pp-2017-0004_ref_026_w2aab3b7c16b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Ma J, Verweij J, Kolker HJ, Van Ingen HE, Stoter G, Schellens JH. Pharmacokinetic-dynamic relationship of cisplatin in vitro: Simulation of an i.v. bolus and 3 h and 20 h infusion. Br J Cancer 1994;69:858\u201362.","DOI":"10.1038\/bjc.1994.166"},{"key":"2025120909204645922_j_pp-2017-0004_ref_027_w2aab3b7c16b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Erlichman C, Vidgen D, Wu A. Antineoplastic drug cytotoxicity in a human bladder cancer cell line: Implications for intravesical chemotherapy. Urol Res 1987;15:13\u201316.","DOI":"10.1007\/BF00256328"},{"key":"2025120909204645922_j_pp-2017-0004_ref_028_w2aab3b7c16b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Sadowitz P, Hubbard B, Dabrowiak J, Goodisman J, Tacka K, Aktas M, et al. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. Drug Metab Dispos 2002;30:183\u201390.","DOI":"10.1124\/dmd.30.2.183"},{"key":"2025120909204645922_j_pp-2017-0004_ref_029_w2aab3b7c16b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M. Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother Pharmacol 1988;21:185\u201390.","DOI":"10.1007\/BF00262767"},{"key":"2025120909204645922_j_pp-2017-0004_ref_030_w2aab3b7c16b1b6b1ab2b1c30Aa","unstructured":"Levasseur L, Slocum H, Rustum Y, Greco W. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res 1998;58:5749\u201361."},{"key":"2025120909204645922_j_pp-2017-0004_ref_031_w2aab3b7c16b1b6b1ab2b1c31Aa","unstructured":"Skipper H. The effects of chemotherapy on the kinetics of leukemic cell behavior. Cancer Res 1965;25:1544\u201350."},{"key":"2025120909204645922_j_pp-2017-0004_ref_032_w2aab3b7c16b1b6b1ab2b1c32Aa","unstructured":"Gardner S. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and-nonspecific drugs. Cancer Res 2000;60:1417\u201325."},{"key":"2025120909204645922_j_pp-2017-0004_ref_033_w2aab3b7c16b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Troger V, Fischel J, Formento P, Gioanni J, Milano G. Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration. Eur J Cancer 1992;28:82\u20136.","DOI":"10.1016\/0959-8049(92)90391-E"},{"key":"2025120909204645922_j_pp-2017-0004_ref_034_w2aab3b7c16b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Kurihara N, Kubota T, Hoshiya Y, Otani Y, Kumai K, Kitajima M. Antitumor activity of cis-diaminedichloroplatinum (II) depends on its time x concentration product against human gastric cancer cell lines in vitro. J Surg Oncol 1995;60:238\u201341.","DOI":"10.1002\/jso.2930600405"},{"key":"2025120909204645922_j_pp-2017-0004_ref_035_w2aab3b7c16b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Shah D, Shin B, Veith J, T\u00f3th K, Bernacki R, Balthasar J. Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. J Pharmacol Exp Ther 2009;329:580\u201391.","DOI":"10.1124\/jpet.108.149443"},{"key":"2025120909204645922_j_pp-2017-0004_ref_036_w2aab3b7c16b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Colin P, De Smet L, Vervaet C, Remon JP, Ceelen W, Van Bocxlaer J, et al. A model based analysis of IPEC dosing of paclitaxel in rats. Pharmaceut Res 2014;31:2876\u201386.","DOI":"10.1007\/s11095-014-1384-5"},{"key":"2025120909204645922_j_pp-2017-0004_ref_037_w2aab3b7c16b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Flessner M, Dedrick R, Schultz J. A distributed model of peritoneal-plasma transport: Theoretical considerations. Am J Physiol 1984;246:597\u2013607.","DOI":"10.1152\/ajpregu.1984.246.4.R597"},{"key":"2025120909204645922_j_pp-2017-0004_ref_038_w2aab3b7c16b1b6b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"Flessner M, Dedrick R, Schultz J. A distributed model of peritoneal-plasma transport: Analysis of experimental data in the rat. Am J Physiol 1985;248:413\u201324.","DOI":"10.1152\/ajprenal.1985.248.3.F413"},{"key":"2025120909204645922_j_pp-2017-0004_ref_039_w2aab3b7c16b1b6b1ab2b1c39Aa","unstructured":"Dedrick R. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985;12:1\u20136."},{"key":"2025120909204645922_j_pp-2017-0004_ref_040_w2aab3b7c16b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"Stachowska-Pietka J, Waniewski J, Flessner M, Lindholm B. Computer simulations of osmotic ultrafiltration and small-solute transport in peritoneal dialysis: A spatially distributed approach. Am J Physiol Ren Physiol 2012;302:1331\u201341.","DOI":"10.1152\/ajprenal.00301.2011"},{"key":"2025120909204645922_j_pp-2017-0004_ref_041_w2aab3b7c16b1b6b1ab2b1c41Aa","doi-asserted-by":"crossref","unstructured":"Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Ren Physiol 2005;288:433\u201342.","DOI":"10.1152\/ajprenal.00313.2004"},{"key":"2025120909204645922_j_pp-2017-0004_ref_042_w2aab3b7c16b1b6b1ab2b1c42Aa","doi-asserted-by":"crossref","unstructured":"El-Kareh A, Secomb T. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia 2004;6:117\u201327.","DOI":"10.1593\/neo.03205"},{"key":"2025120909204645922_j_pp-2017-0004_ref_043_w2aab3b7c16b1b6b1ab2b1c43Aa","unstructured":"Chato J. Thermal properties of tissues.. In: Skalak R, Chien S, Eds.. Handbook of Bioengineering. New York: McGraw-Hill, 1987:9.1\u20139.13."},{"key":"2025120909204645922_j_pp-2017-0004_ref_044_w2aab3b7c16b1b6b1ab2b1c44Aa","doi-asserted-by":"crossref","unstructured":"Eichholtz-Wirth H, Hietel B. Heat sensitization to cisplatin in two cell lines with different drug sensitivities. Int J Hypertherm 1990;6:47\u201355.","DOI":"10.3109\/02656739009140803"},{"key":"2025120909204645922_j_pp-2017-0004_ref_045_w2aab3b7c16b1b6b1ab2b1c45Aa","doi-asserted-by":"crossref","unstructured":"Kusumoto T, Maehara Y, Baba H, Takahashi I, Kusumoto H, Ohno S, et al. Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxicity and intracellular platinum accumulation in HeLa cells. Br J Cancer 1993;68:259\u201363.","DOI":"10.1038\/bjc.1993.324"},{"key":"2025120909204645922_j_pp-2017-0004_ref_046_w2aab3b7c16b1b6b1ab2b1c46Aa","doi-asserted-by":"crossref","unstructured":"Hettinga J, Konings A, Kampinga H. Reduction of cellular cisplatin resistance by hyperthermia\u2014A review. Int J Hypertherm 1997;13:439\u201357.","DOI":"10.3109\/02656739709023545"},{"key":"2025120909204645922_j_pp-2017-0004_ref_047_w2aab3b7c16b1b6b1ab2b1c47Aa","doi-asserted-by":"crossref","unstructured":"Au J, Guo P, Gao Y, Lu Z, Wientjes M, Tsai M, et al. Multiscale tumor spatiokinetic model for intraperitoneal therapy. AAPS J 2014;16:424\u201339.","DOI":"10.1208\/s12248-014-9574-y"},{"key":"2025120909204645922_j_pp-2017-0004_ref_048_w2aab3b7c16b1b6b1ab2b1c48Aa","doi-asserted-by":"crossref","unstructured":"Baxter L, Jain R. Transport of fluid and macromolecules in tumors I. Role of interstitial pressure and convection. Microvasc Res 1989;37:77\u2013104.","DOI":"10.1016\/0026-2862(89)90074-5"},{"key":"2025120909204645922_j_pp-2017-0004_ref_049_w2aab3b7c16b1b6b1ab2b1c49Aa","doi-asserted-by":"crossref","unstructured":"Tsai M, Lu Z, Wang J, Yeh T, Wientjes M, Au J. Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharm Res 2007;24:1691\u2013701.","DOI":"10.1007\/s11095-007-9298-0"},{"key":"2025120909204645922_j_pp-2017-0004_ref_050_w2aab3b7c16b1b6b1ab2b1c50Aa","doi-asserted-by":"crossref","unstructured":"Lu Z, Tsai M, Lu D, Wang J, Wientjes M, Au J. Tumor- penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther 2008;327:673\u201382.","DOI":"10.1124\/jpet.108.140095"},{"key":"2025120909204645922_j_pp-2017-0004_ref_051_w2aab3b7c16b1b6b1ab2b1c51Aa","doi-asserted-by":"crossref","unstructured":"Steuperaert M, Falvo D\u2019Urso Labate G, Debbaut C, De Wever O, Vanhove C, Ceelen W, et al. Mathematical modeling of intraperitoneal drug delivery: Simulation of drug distribution in a single tumor nodule. Drug Deliv 2017;24:491\u2013501.","DOI":"10.1080\/10717544.2016.1269848"},{"key":"2025120909204645922_j_pp-2017-0004_ref_052_w2aab3b7c16b1b6b1ab2b1c52Aa","doi-asserted-by":"crossref","unstructured":"Gremonprez F, Descamps B, Izmer A, Vanhove C, Vanhaecke F, De Wever O, et al. Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model. Oncotarget 2015;6:29889\u2013900.","DOI":"10.18632\/oncotarget.5092"},{"key":"2025120909204645922_j_pp-2017-0004_ref_053_w2aab3b7c16b1b6b1ab2b1c53Aa","doi-asserted-by":"crossref","unstructured":"Winner K, Steinkamp M, Lee R, Swat M, Muller C, Moses M, et al. Spatial modeling of drug delivery routes for treatment of disseminated ovarian cancer. Cancer Res 2016;76:1320\u201334.","DOI":"10.1158\/0008-5472.CAN-15-1620"},{"key":"2025120909204645922_j_pp-2017-0004_ref_054_w2aab3b7c16b1b6b1ab2b1c54Aa","doi-asserted-by":"crossref","unstructured":"Cickovski T, Aras K, Alber M, Izaguirre J, Swat M, Glazier J, et al. From genes to organisms via the cell: A problem-solving environment for multicellular development. Comp Sci Eng 2007;9:50\u201360.","DOI":"10.1109\/MCSE.2007.74"},{"key":"2025120909204645922_j_pp-2017-0004_ref_055_w2aab3b7c16b1b6b1ab2b1c55Aa","doi-asserted-by":"crossref","unstructured":"Swat M, Hester S, Balter A, Heiland R, Zaitlen B, Glazier J. Multicell simulations of development and disease using the CompuCell3D simulation environment. Methods Mol Biol 2009;500:361\u2013428.","DOI":"10.1007\/978-1-59745-525-1_13"},{"key":"2025120909204645922_j_pp-2017-0004_ref_056_w2aab3b7c16b1b6b1ab2b1c56Aa","doi-asserted-by":"crossref","unstructured":"Steinkamp M, Winner K, Davies S, Muller C, Zhang Y, Hoffman R, et al. Ovarian tumor attachment, invasion, and vascularization reflect unique microenvironments in the peritoneum: Insights from xenograft and mathematical models. Front Oncol 2013;3:97.","DOI":"10.3389\/fonc.2013.00097"},{"key":"2025120909204645922_j_pp-2017-0004_ref_057_w2aab3b7c16b1b6b1ab2b1c57Aa","doi-asserted-by":"crossref","unstructured":"Wu M, Frieboes H, McDougall S, Chaplain M, Cristini V, Lowengrub J. The effect of interstitial pressure on tumor growth: Coupling with the blood and lymphatic vascular systems. Journal Theor Biol 2013;320:131\u201351.","DOI":"10.1016\/j.jtbi.2012.11.031"},{"key":"2025120909204645922_j_pp-2017-0004_ref_058_w2aab3b7c16b1b6b1ab2b1c58Aa","doi-asserted-by":"crossref","unstructured":"Kim E, Stamatelos S, Cebulla J, Bhujwalla Z, Popel A, Pathak A. Multiscale imaging and computational modeling of blood flow in the tumor vasculature. Ann Biomed Eng 2012;40:2425\u201341.","DOI":"10.1007\/s10439-012-0585-5"},{"key":"2025120909204645922_j_pp-2017-0004_ref_059_w2aab3b7c16b1b6b1ab2b1c59Aa","doi-asserted-by":"crossref","unstructured":"Venkatasubramanian R, Arenas R, Henson M, Forbes N. Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response. Brit J Cancer 2010;103:486\u201397.","DOI":"10.1038\/sj.bjc.6605773"},{"key":"2025120909204645922_j_pp-2017-0004_ref_060_w2aab3b7c16b1b6b1ab2b1c60Aa","doi-asserted-by":"crossref","unstructured":"Goh Y, Kong H, Wang C. Simulation of the delivery of doxorubicin to hepatoma. Pharm Res 2001;18:61\u2013770.","DOI":"10.1023\/A:1011076110317"},{"key":"2025120909204645922_j_pp-2017-0004_ref_061_w2aab3b7c16b1b6b1ab2b1c61Aa","doi-asserted-by":"crossref","unstructured":"Arifin D, Yiu K, Lee T, Wang C. Chemotherapeutic drug transport to brain tumor. J Control Release 2009;137:203\u201310. DOI:10.1016\/j.jconrel.2009.04.013.","DOI":"10.1016\/j.jconrel.2009.04.013"},{"key":"2025120909204645922_j_pp-2017-0004_ref_062_w2aab3b7c16b1b6b1ab2b1c62Aa","doi-asserted-by":"crossref","unstructured":"Linninger A, Somayaji M, Mekarski M, Zhang L. Prediction of convection-enhanced drug delivery to the human brain. J Theor Biol 2008;250:125\u201338.","DOI":"10.1016\/j.jtbi.2007.09.009"},{"key":"2025120909204645922_j_pp-2017-0004_ref_063_w2aab3b7c16b1b6b1ab2b1c63Aa","doi-asserted-by":"crossref","unstructured":"Tan W, Wang F, Lee T, Wang CH. Computer simulation of the delivery of etanidazole to brain tumor from PLGA wafers: Comparison between linear and double burst release systems. Biotechnol Bioeng 2003;82:278\u201388.","DOI":"10.1002\/bit.10571"},{"key":"2025120909204645922_j_pp-2017-0004_ref_064_w2aab3b7c16b1b6b1ab2b1c64Aa","doi-asserted-by":"crossref","unstructured":"Thurber G, Yang K, Reiner T, Kohler R, Sorger P, Mitchison T, et al. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat Commun 2013;4:1504.","DOI":"10.1038\/ncomms2506"},{"key":"2025120909204645922_j_pp-2017-0004_ref_065_w2aab3b7c16b1b6b1ab2b1c65Aa","doi-asserted-by":"crossref","unstructured":"Ait-Oudhia S, Straubinger R, Mager D. Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy. J Pharmacol Exp Ther 2013;344:103\u201312.","DOI":"10.1124\/jpet.112.199109"},{"key":"2025120909204645922_j_pp-2017-0004_ref_066_w2aab3b7c16b1b6b1ab2b1c66Aa","doi-asserted-by":"crossref","unstructured":"Ye H, Tanenbaum L, Na Y, Mantzavinou A, Fulci G, Del Carmen M, et al. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. J Control Release 2015;220:358\u201367.","DOI":"10.1016\/j.jconrel.2015.11.001"},{"key":"2025120909204645922_j_pp-2017-0004_ref_067_w2aab3b7c16b1b6b1ab2b1c67Aa","doi-asserted-by":"crossref","unstructured":"Kim M, Gillies R, Rejniak K. Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues. Front Oncol 2013;3:278.","DOI":"10.3389\/fonc.2013.00278"},{"key":"2025120909204645922_j_pp-2017-0004_ref_068_w2aab3b7c16b1b6b1ab2b1c68Aa","doi-asserted-by":"crossref","unstructured":"Deisboeck T, Wang Z, Macklin P, Cristini V. Multiscale cancer modeling. Annu Rev Biomed Eng 2011;13. DOI:10.1146\/annurev-bioeng-071910-124729.","DOI":"10.1146\/annurev-bioeng-071910-124729"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/2\/2\/article-p73.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0004\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0004\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:40:15Z","timestamp":1765276815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0004\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,14]]},"references-count":68,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6,6]]},"published-print":{"date-parts":[[2017,6,5]]}},"alternative-id":["10.1515\/pp-2017-0004"],"URL":"https:\/\/doi.org\/10.1515\/pp-2017-0004","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4,14]]}}}